Data from the phase 3 METEOR trial presented at the 2016 annual meeting of the American Society of Clinical Oncology showed that cabozantinib reduced the risk of death in patients with advanced renal cell carcinoma by 34%, compared with everolimus.
Published Online: July 22, 2016
Jason M. Broderick
Cabozantinib (Cabometyx) reduced the risk of death by 34% compared with everolimus (Afinitor) in patients with previously treated advanced renal cell carcinoma (RCC), according to updated data from the phase 3 METEOR trial presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO).1
The results, which were simultaneously published in The Lancet Oncology,2
showed a 4.9-month median overall survival (OS) benefit with cabozantinib. The risk of disease progression was reduced by 49% with the multi kinase inhibitor versus everolimus. Based on the METEOR trial’s results, the FDA approved cabozantinib in April 2016 for patients with advanced RCC who had prior antiangiogenic therapy.3
“In the phase 3 METEOR trial, treatment with cabozantinib was associated with a significant improvement in overall survival, as well as progression-free survival and objective response rate compared with everolimus in patients with advanced renal cell carcinoma. Cabozantinib is a new standard for patients with advanced RCC after prior antiangiogenic therapy,” lead author Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, said when presenting the data at ASCO.
The complete article can be accessed here: http://bit.ly/29Qpg9I
Jason M. Broderick is associate director, Digital Editorial, OncLive.com.